STAT+: Why these health tech leaders are making a risky bet, openly backing Trump or Harris
Silicon Valley startup founders and venture capital investors are picking a side in this year’s…
Category: startups
STAT+: Startup Q Bio raises $27 million to build its own full-body scanner
A prevention-focused co-founded by the head of a Stanford research lab is making an expensive…
STAT+: Data privacy startup raises $30 million, to ease health care providers’ regulatory burden
Federal guidance restricting hospital websites’ use of third-party trackers along with the proliferation of direct-to-consumer…
STAT+: Are expensive whole-body MRI scans medically useful? A new clinical trial aims to find out
A startup selling elective whole-body scans for upward of $1,000 is launching a 10-year, 100,000…
STAT+: Transcarent, Glen Tullman’s health tech unicorn, raises $126 million
Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman,…
Listen: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
How does a startup compete with the likes of Eli Lilly and Novo Nordisk in…
.jpg)
Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Why is it surprising when drug executives stay true to their word? And can neoantigen…
STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO
Robert Ross had thought he would take more time off after his previous company, Surface…
STAT+: As AI marches into medicine, investors eye security, privacy startups
Investors are starting to back startups that offer privacy and security services to bolster health…
Startup Alumis raises $259 million as it prepares for psoriasis trial
San Francisco startup Alumis Inc. has raised $259 million in a bid to best big…
STAT+: Biotech launches with $82 million for Parkinson’s cell therapy
The dream of being able to pluck a cell therapy off of a freezer shelf…
Q&A: A biotech VC leader shares her next big bets
Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners,…
STAT+: As regulators play catch up with AI, tech startups say uncertainty is slowing them down
The federal government’s plan to boost its oversight of the use of artificial intelligence tools…
STAT+: Flagship Pioneering startup lays off a third of staff
Sonata Therapeutics, a startup created two years ago through the merger of two Flagship Pioneering…
STAT+: Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million
John Puisis was dubious when he first heard about the autoimmune science being developed by…
STAT+: Physician buy-in will make or break VC firm General Catalyst’s bold hospital deal
It makes sense in theory for hospitals and startups to strike deals. Not only would…
Biotech layoffs, slumping stocks, and a 2024 preview
Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going…
STAT+: Dewpoint Therapeutics cuts 15% of staff, acknowledges Merck, Pfizer broke off partnerships over buzzy science
Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular…
STAT+: What to expect from hospitals and health insurers at this year’s JPM Healthcare Conference
Nonprofit hospitals often get overshadowed at the J.P. Morgan Healthcare Conference, the health care industry’s…
STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff
Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve…
STAT+: Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics
Veteran biotech entrepreneur Harvey Berger, who has been on the sidelines for the past five…
STAT+: LabCentral, a crucial incubator for local drug discovery, is slated to grow amid industry slowdown
CAMBRIDGE — Vietnamese-born entrepreneur Jean Pham is “graduating” from LabCentral, a biotech launchpad on the…
Violet CEO on measuring clinician inclusiveness: ‘It’s almost like a credit score’
PHOENIX, Ariz. — Gaurang Choksi is the founder and CEO of Violet, a health equity…
STAT+: 3 medtech trends to watch in 2024
It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was…
STAT+: Health tech investors are getting selective. Expect slow growth, consolidation
Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to…
STAT+: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells
David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching…
Digital health funding stays low as a new reality sets in
You’re reading the web edition of STAT Health Tech, our guide to how tech is…
STAT+: One of biotech’s biggest financiers launches small-molecule startup, in spite of IRA’s looming shadow
It’s been nearly a year since Congress passed the Inflation Reduction Act, raising a chorus…
STAT+: In Silicon Valley, a venture capital firm gives health tech startups a crash course in getting paid
REDWOOD CITY, Calif. — Over two blustery spring days earlier this month, 30 hopeful tech…
Opinion: What the recent failures of Mindstrong and Pear tell us about the future of digital mental health
Over the past five years, digital mental health has risen from a niche topic to…
STAT+: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM
Marianne De Backer’s iPhone calendar is a solid block of green. De Backer, the head…
BIO’s messy transition, mRNA’s future, & Biogen’s next CEO
What’s going on at biotech’s lobbying organization? Where does mRNA go from here? And what…
These 3 startups are trying to improve diversity in clinical trials, a challenge experts say will take more than just tech
A host of health tech startups and companies are advertising their apps and platforms as…
STAT+: Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight
At the start of 2021, blue-chip biotech investor ARCH Venture Partners and a relatively unknown…
STAT+: When biotech acquisitions spike, early-stage startups are prime targets, analysis shows
Experts are predicting a coming surge of mergers and acquisitions in biotech. And if history…
.jpg)
STAT+: 3 biotech trends to watch in 2022
It’s been a weird year for biotech stocks. One major index peaked in February, but…
STAT+: Biotech investor Eli Casdin on biotech’s bad December
Biotech investors are having some not-so-happy holidays. In the last few months, several major funds…
STAT+: At biotech venture capital firms, collecting ‘consulting fees’ from startups has become widespread
Some of the biggest names in biotech venture capital have charged their startups millions of…
STAT+: Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s
Flagship Pioneering is gearing up to launch a new company that seems to be developing…
STAT+: 4 food allergy immunotherapy companies to watch
More and more children are developing food allergies — and biotech companies are springing up…
STAT+: Moderna, making billions from its vaccine, bets on a genome-editing startup
Moderna, flush with cash thanks to its blockbuster Covid-19 vaccine, made waves back in August…
STAT+: In the ‘fail fast’ world of biotech, ‘offboarding’ is just as important as onboarding
In today’s biotech job market — where competition for people with in-demand experience is fiercer…
STAT+: In another sign of RNA’s growing popularity, the cancer startup Replicate is relaunching
A California startup is putting a new spin on a now-familiar idea: using RNA as…
STAT+: Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms
Flagship Pioneering is on track to return its investors’ money an eye-popping 15 times over,…
STAT+: Startup Spotlight: Vigil Neuroscience hopes to eventually target the rare disease ALSP
Vigil Neuroscience has revealed the first condition that it will target: a rare, genetic neurodegenerative…
STAT Plus: How much is a startup worth? For biotech companies, the answer is rarely public
Valuations are fundamental information about any startup. Not only can high valuations give a company…